- |||||||||| KRAS-G12V TCR-modified T-cell therapy / Anocca
Development of a clinical candidate TCR for mutant KRAS using a high-precision cell-based platform (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_740;
Herein, we describe use of the platform to perform target quantification and to generate a clinical candidate TCR recognizing the 10mer peptide derived from the KRAS G12V mutant form presented in HLA-A*11:01...Primary CD8 cells were transduced by insertional gene editing, generating a TCR-product with high levels of surface TCR and potent cytotoxic action. Conclusions The TCR-T product is now being advanced to clinical trial and is designed to be the first entry in a broader program covering multiple HLA restrictions and mutant KRAS epitopes.
|
